Shares in DexCom Inc. (NSDQ:DXCM) jumped 9% today after the Centers for Medicare & Medicaid Services updated the criteria for coverage of the company’s G5 Mobile continuous glucose monitor. The device is the only therapeutic CGM classified as durable medical equipment under Medicare Part B.
Patients covered by Medicare who have Type I or II diabetes and intensively manage their insulin will be able to obtain reimbursement, according to the updated criteria.
Get the full story at our sister site, Drug Delivery Business News.
The post CMS updates on criteria for Dexcom G5 coverage appeared first on MassDevice.
from MassDevice http://ift.tt/2nwrh0v
Cap comentari:
Publica un comentari a l'entrada